<table border="1"><tr><th>Name UICPA</th><td><ul><li>N-(2-(4-(4-fluorobenzylcarbamoyl) -5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine -2-yl)propan-2-yl)-5-methyl -1,3,4-oxadiazole-2-carboxamide</li></ul></td></tr><tr><th>N | o | CAS</th><td><ul><li>518048-05-0</li></ul></td></tr><tr><th>N | o | ECHA</th><td><ul><li>100.124.631</li></ul></td></tr><tr><th>ATC Code</th><td><ul><li>J05 | AX08</li></ul></td></tr><tr><th>PubChem</th><td><ul><li>54671008</li></ul></td></tr><tr><th>SMILES</th><td><ul><li>Cc1nnc(o1)C(=O)NC(C)(C)C3=NC(C(=O)NCc2ccc(F)cc2)=C(O)C(=O)N3C | PubChem |, | 3D view</li></ul></td></tr><tr><th>InChI</th><td><ul><li>InChI | 3D view | InChI=1/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) | InChIKey | CZFFBEXEKNGXKS-UHFFFAOYSA-N</li></ul></td></tr><tr><th>Formula</th><td><ul><li>C | 20 | H | 21 | FN | 6 | O | 5 | [Isomeres]</li></ul></td></tr><tr><th>Molar mass</th><td><ul><li>444.4163 Â± 0.0202 g/mol | C 54.05 %, H 4.76%, F 4.27%, N 18.91%, O 18%,</li></ul></td></tr><tr><th>Bioavailability</th><td><ul><li>good</li></ul></td></tr><tr><th>Therapeutic class</th><td><ul><li>Antiretroviral: Integrase inhibitor</li></ul></td></tr><tr><th>Route of administration</th><td><ul><li>Oral</li></ul></td></tr><tr><th>Pregnancy</th><td><ul><li>Contra-indicated | (category C)</li></ul></td></tr><tr><th>Precautions</th><td><ul><li>monitoring creatine kinase</li></ul></td></tr></table>